Lusine Demikhanyan

Dr. Lusine Demikhanyan

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2024 in Cells
Verified
Journal Article
Open access
PDF file
CCClare Chen
Clare Chen
LDLusine Demikhanyan
Lusine Demikhanyan
CGChristopher Gondi
Christopher Gondi
With the lack of specific signs and symptoms, pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among various biomarkers, microRNA-21 (miR-21), a small non-coding RNA, is highly expressed in PDAC. By inhibiting regulatory proteins at the 3′ untranslated regions (UTR), miR-21 holds significant roles in PDAC cell proliferation, epithelial–mesenchymal transition, angiogenesis, as well as cancer invasion, metastasis, and resistance therapy. We conducted a systematic search across major databases for articles on miR-21 and pancreatic cancer mainly published within the last decade, focusing on their diagnostic, prognostic, therapeutic, and biological roles. This rigorous approach ensured a comprehensive review of miR-21’s multifaceted role in pancreatic cancers. In this review, we explore the current understandings and future directions regarding the regulation, diagnostic, prognostic, and therapeutic potential of targeting miR-21 in PDAC. This exhaustive review discusses the involvement of miR-21 in proliferation, epithelial–mesenchymal transition (EMT), apoptosis modulation, angiogenesis, and its role in therapy resistance. Also discussed in the review is the interplay between various molecular pathways that contribute to tumor progression, with specific reference to pancreatic ductal adenocarcinoma.

Verified
Journal Article
Open access
PDF file
CCClare Chen
Clare Chen
APAmeena Patel
Ameena Patel
LDLusine Demikhanyan
Lusine Demikhanyan
CGChristopher Gondi
Christopher Gondi
Mucin, a heavily glycosylated glycoprotein, serves an important function in forming protective and immune defense barriers against the exterior environment on epithelial surfaces. While secreted-type mucins are involved in mucous production, transmembrane mucins, which contain O-glycosylated tandem repeats, play a pivotal role in cellular signaling, especially in immune modulation and mediating inflammatory response. However, dysregulation in mucin expressions, such as MUC1, MUC2, MUC4, MUC5AC, and MUC16, have been observed in many cancer cells. More specifically, alterations in the expression and glycosylation of MUC1 have been associated with the upregulation of pathways involving the cell proliferation, angiogenesis, migration, and invasion of cancer cells. With mucin’s extensive involvement in cancer biology, several mucin biomarkers, such as CA125, CA19-9, and CEA, have been utilized as diagnostic and prognostic monitoring biomarkers in ovarian, pancreatic, and colon cancer. Vaccines and antibody therapy against abnormal mucin glycosylation have also been investigated for potential therapy for mucin-related cancers that are resistant to traditional chemotherapy agents. Despite the lack of specificity in mucin biomarkers and challenges in efficient drug delivery systems, the current advancement in mucin-targeted immunotherapy highlighted the pivotal potential in developing therapeutic targets to improve cancer prognosis.

12 June 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
ZCZaphrirah S. Chin
Zaphrirah S. Chin
AGArshia Ghodrati
Arshia Ghodrati
MFMilind Jonathan Foulger
Milind Jonathan Foulger
LDLusine Demikhanyan
Lusine Demikhanyan
CGChristopher Gondi
Christopher Gondi
Healthcare disparities in cancer care remain pervasive, driven by intersecting socioeconomic, racial, and insurance-related inequities. These disparities manifest in various forms such as limited access to medical resources, underrepresentation in clinical trials, and worse cancer outcomes for marginalized groups, including low-income individuals, racial minorities, and those with inadequate insurance coverage, who face significant barriers in accessing comprehensive cancer care. This manuscript explores the multifaceted nature of these disparities, examining the roles of socioeconomic status, race, ethnicity, and insurance status in influencing cancer care access and outcomes. Historical and contemporary data highlight that minority racial status correlates with reduced clinical trial participation and increased cancer-related mortality. Barriers such as insurance coverage, health literacy, and language further hinder access to cancer treatments. Addressing these disparities requires a systemic approach that includes regulatory reforms, policy changes, educational initiatives, and innovative trial and treatment designs. This manuscript emphasizes the need for comprehensive interventions targeting biomedicine, socio-demographics, and social characteristics to mitigate these inequities. By understanding the underlying causes and implementing targeted strategies, we can work towards a more equitable healthcare system. This involves improving access to high-quality care, increasing participation in research, and addressing social determinants of health. This manuscript concludes with policy recommendations and future directions to achieve health equity in cancer care, ensuring optimal outcomes for all patients.

2 February 2025 in Pathophysiology
Verified
Journal Article
Open access
PDF file
SAShalan Alaamri
Shalan Alaamri
ASAbdulhalim S Serafi
Abdulhalim S Serafi
ZHZahir Hussain
Zahir Hussain
SBShouq K. Bafail
Shouq K. Bafail
MBMohammed A. Bafail
Mohammed A. Bafail
SSSumera Sohail
Sumera Sohail
Background/Objectives: One of the major causes of hypertension (HT) is the transition of normal weight (NW) status to overweight (OW) status and obesity in a population, which leads to cardiovascular disease (CVD) and other disorders. A variety of factors/variables are involved in the development of HT and OW-related hypertension (OHT). However, we planned to investigate the pathophysiological role of serum leptin (Lep), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), total cholesterol (TC) and serum testosterone (ST) in OHT in middle-aged men. Methods: We consulted three groups of middle-aged men (age: 51–60 years)—an HT group (n: 97, high normal weight (HNW), body mass index (BMI): 23–24.9 kg/m2); an OHT group (n: 97, high overweight (HOW), BMI: 28–29.9 kg/m2) and a normal control group (NC, n: 98, HNW)—to investigate the variations in and correlations of Lep, IL-6, TNF-α, ST, TC and other variables. Results: Significant variations were obtained for the comparisons of TNF-α, Lep, ST and TC for the patient groups. OHT vs. NC showed a significant difference for ST. OHT vs. NC and OHT vs. HT had significant variations for IL-6. Significant changes were obtained for the serum levels of TNF-α, Lep, IL-6, ST and TC among groups. Significant and positive linear associations were obtained for TNF-α, Lep, TC and IL-6. Significant and negative linear associations were found for ST plotted against Lep, TNF-α and IL-6. Conclusions: The current report provides pathophysiological evidence of the interactive role of serum Lep, TNF-α, ST, TC and IL-6 in middle-aged men with HT and OHT. We suggest that the changes we noted in the present study would be helpful for further BMI-based studies in various subcategories of NW, OW and obese subjects with/without HT.

1 February 2017 in Biophysical Journal
Verified
Journal Article
Closed access
YNYelena Nersesyan
Yelena Nersesyan
LDLusine Demikhanyan
Lusine Demikhanyan
TDTyler Dawson
Tyler Dawson
SASwapna Asuthkar
Swapna Asuthkar
DCDeny Cabezas-Bratesco
Deny Cabezas-Bratesco
EZEleonora Zakharian
Eleonora Zakharian

21 October 2025 in Journal of Innovative Solutions for Eco-Environmental Sustainability
Verified
Journal Article
Open access
PDF file
LDLusine Demikhanyan
Lusine Demikhanyan
MGManu Gnanamony
Manu Gnanamony
CGChristopher S. Gondi
Christopher S. Gondi
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by challenges in social interaction, communication, and the presence of restricted and repetitive behaviors. While the neurobiological underpinnings of ASD remain elusive, understanding the function of individual neurons and their integration into circuits is critical. The zebrafish (Danio rerio) offers a powerful model system for dissecting neural circuit function due to its genetic tractability, external development, larval transparency, and conserved neuroanatomy. This presentation highlights the utility of the zebrafish model for investigating ASD-relevant neural circuitry through a combined in vitro and in vivo approach. We focus on isolating specific neuronal populations from zebrafish models of ASD to perform in vitro electrophysiological recordings, characterizing their intrinsic electrical properties and synaptic signaling deficits at the single-cell level. These in vitro findings regarding altered neuronal excitability and connectivity are then validated in vivo by assessing corresponding behavioral phenotypes in intact zebrafish larvae using established paradigms for social interaction, locomotion, and sensory processing. By correlating cellular-level electrical dysfunction observed in vitro with circuit-level activity and complex behaviors in vivo, we aim to bridge the gap between molecular/cellular deficits and the emergent behavioral characteristics of ASD. This integrated approach using the zebrafish model provides a valuable platform for identifying specific neuronal contributions to ASD pathophysiology and offers potential avenues for high-throughput screening of therapeutic interventions targeting neuronal function. The insights gained from these studies contribute to a more comprehensive understanding of ASD neurobiology and facilitate the translation of findings towards clinical applications.